Rakovina Net Income Applicable To Common Shares from 2010 to 2024

Stocks . Canada . 
Stock . Rakovina Therapeutics
RKV Stock  CAD 0.14  0.02  16.67%   
Rakovina Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-5 M
Current Value
-4.7 M
Quarterly Volatility
2.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rakovina Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rakovina Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 158.9 K, Interest Income of 21.7 K or Selling General Administrative of 706.8 K, as well as many indicators such as . Rakovina financial statements analysis is a perfect complement when working with Rakovina Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Rakovina Therapeutics Technical models . Check out the analysis of Rakovina Therapeutics Correlation against competitors.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Rakovina Stock Analysis

When running Rakovina Therapeutics' price analysis, check to measure Rakovina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rakovina Therapeutics is operating at the current time. Most of Rakovina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rakovina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rakovina Therapeutics' price. Additionally, you may evaluate how the addition of Rakovina Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY